about
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcomaAntitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patientsRetrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trialVenous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer NetworkEfficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective studyTrabectedin therapy for sarcomas.Uterine sarcomas: a multidisciplinary challenge.ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.Long-term morbidity after multivisceral resection for retroperitoneal sarcoma.Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization fCorrelation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: analysis of 291 consecutive patients at a tertiary reference sarcoma center.Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.The intriguing patterns of tumor response to trabectedin.Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas.Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.Mode of action of trabectedin in myxoid liposarcomas.Role of Macrophage Targeting in the Antitumor Activity of TrabectedinIn vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneumGemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer NetworkMyogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal LiposarcomaMyxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single InstitutionPersonalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended ResectionTrabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers
P50
Q33371397-43455496-1DC4-4C75-A3F5-E2F7A1561280Q33420031-35C7F8A0-2DD4-472F-8E4E-FFCA13248C9EQ34102992-18385C8F-C35A-4AAB-A413-78C6CCE40F5FQ34608105-72092E96-C6D2-4445-B014-F5F47B11DE8AQ35098302-E7F7C9F2-3FAC-44DB-8C9E-401D79EAA7A8Q35244168-FF5CA9D5-2751-41D7-AA94-9D4D35FF4153Q36166850-DE1B1C05-3300-4316-9767-E5F5ECD5BD9FQ36514001-88DE7EA0-34CB-49E0-A41C-AE48645099C6Q36856816-074B6760-626F-4C50-B7C8-46536970A900Q37427998-E0D90ECB-F9DF-454E-9089-F3D1940739E3Q37758105-E1AE9105-FA89-49B4-B4B6-EC1F9CFEDFFFQ37937890-F47BA9C6-4AA9-46B4-9DC1-CF1F4ED41F11Q38337608-1DE4DAE6-975F-4086-92C8-060D425503CFQ40871123-AF0C13C9-8DE6-4CA1-B1D9-7777E4CE0868Q41701973-68811E86-4642-4A27-8813-F1F3ECE425B3Q41749275-BC0F64B8-FCD0-4071-85B4-6DEAE8CD1D17Q42928532-BD57F974-CB4B-4EEE-8355-B97EFCC29CE9Q43045056-391FE8DE-941B-4961-B8CA-2007C21823B1Q43756770-A4118CA7-031F-4B98-8486-A9DD0E2BC729Q44410669-FD6ADC38-1C2F-41C0-8D3A-BC4613B1C8E9Q44481728-323AC862-4F68-4C08-8CC4-94CD9DC73B1EQ45346605-4E6F9E73-CD03-4A07-8667-ADED8950055EQ56942258-5D174775-E7F7-4EA6-8AA2-BEB0423B29D6Q58813285-7008F695-D00E-4F18-AB88-80AB0AA41083Q60048095-19736B9D-7D87-4CBF-B1F3-E7F6DB562F3BQ60618081-4A8B402F-433A-42F8-8D3C-AC81597E86EEQ60618087-CDFEA886-F9F1-4756-915D-C4F55356E1C0Q61040877-4211BC7E-F8E0-49EB-813D-9416848DFE38Q61040879-4BE1CD78-4336-4AAD-A866-47440850C8C7Q61794108-627401D1-B668-4D60-B2D9-4E563CF61FF7Q61794170-54A63859-6051-4F66-A055-5717B18C0032
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Roberta Sanfilippo
@ast
Roberta Sanfilippo
@en
Roberta Sanfilippo
@es
Roberta Sanfilippo
@nl
Roberta Sanfilippo
@sl
type
label
Roberta Sanfilippo
@ast
Roberta Sanfilippo
@en
Roberta Sanfilippo
@es
Roberta Sanfilippo
@nl
Roberta Sanfilippo
@sl
prefLabel
Roberta Sanfilippo
@ast
Roberta Sanfilippo
@en
Roberta Sanfilippo
@es
Roberta Sanfilippo
@nl
Roberta Sanfilippo
@sl
P1053
E-2123-2017
P106
P1153
36464099700
P21
P31
P3829
P496
0000-0002-9704-0521